Other

University of Florida Research Foundation, Incorporated

Apollo Genetics

Katherine D Gordon

James W Simpkins

Robert J Leonard

Pattie S Green

The present invention provides methods of conferring protection on a population of cells associated with ischemia in a subject following an ischemic event, comprising: (a) providing an estrogen compound; and (b) administering the effective amount of the compound over a course that includes at least one dose within a time that is effectively proximate to the ischemic event, so as to confer protection on the population of cells. Novel methods are provided for the delivery of an estrogen compound. Examples of ischemic events treatable according to the invention are cerebrovascular disease or stroke, subarachnoid subhemorrhage, myocardial infarct, surgery and trauma. A method of treating ischemic damage utilizing non-sex hormones is also provided.

Methods of prevention and treatment of ischemic damage

The present invention provides methods of conferring protection on a population of cells associated with ischemia in a subject following an ischemic event, comprising: (a) providing an estrogen compound; and (b) administering the effective amount of the compound over a course that includes at least one dose within a time that is effectively proximate to the ischemic event, so as to confer protection on the population of cells. Novel methods are provided for the intravenous administration of an estrogen compound. Examples of ischemic events treatable according to the invention are cerebrovascular disease or stroke, subarachnoid subhemorrhage, myocardial infarct, surgery and trauma. A method of treating ischemic damage utilizing non-sex hormones is also provided.

The invention comprises methods for conferring a cytoprotective effect on a population of cells, such as providing a polycyclic phenolic compound in a physiologically acceptable formulation, and administering the formulation in an effective dose to the population of cells.

Cytoprotective effect of polycyclic phenolic compounds

A method is provided for conferring neuroprotection on a population of cells in a subject, the method including providing a polycyclic compound having a terminal phenolic group in a structure containing at least a second ring, the compound having a molecular weight of less than 1000 Daltons, the compound not including estrogen compounds including estrogen agonists. The compound may be administered in an effective dose to the population of cells so as to confer neuroprotection. Methods are further provided for treating a neurodegenerative disease in a subject that include providing an effective dose of a formulation containing the compound and administering the dose to the subject.

Neuroprotective effects of polycyclic phenolic compounds

Androgens and their derivates and analogs, such as anabolic agents, are characterized by at least one substituent or substituent grouping with radical trapping properties. These compounds are used as androgen or anabolic agent substitutes or therapeutical agents for treating androgen defficiency; for treating benign prostate hypertrophy and prostate carcinome, in particular with a testosterone-based compound; for treating osteoporosis, in particular post-menopausal osteoporosis in women, preferably associated with estrogen and/or gestagens; for treating brain oedema induced by vasculary or ischemic troubles, subarachnoidal bleeding, ischemic shock and cerebral insult; for treating asthma in its various forms, for treating Alzheimer's disease, Parkinson's disease; for organ transplants; and for treating androgen-dependent and non androgen-dependent malign neoplasia

Testosterone compounds and use for the protection of neurons

This application relates to the use of non-estrogen compounds having a terminal phenol group in a four-ring cyclopentanophenanthrene compound structure for conferring neuroprotection to cells and for the treatment of neurodegenerative diseases.

Growing community of inventors

Winchester, MA, United States of America

Katherine D Gordon